Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malaria

Free Subscription Articles published in Vaccine Retrieve available abstracts of 24 articles: HTML format

Single Articles

September 2025
1. ZHAO Z, Ma X, Milligan P, Cheung YB, et al
   Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
   Vaccine. 2025;63:127673.
   PubMed     Abstract available
   
   
   July 2025
2. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
   Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
   Vaccine. 2025;60:127323.
   PubMed     Abstract available
   
   
   June 2025
3. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
   Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
   Vaccine. 2025;61:127376.
   PubMed     Abstract available
   
   
   May 2025
4. YUN SY, Nguyen MN, Hong H, Bae GJ, et al
   Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii.
   Vaccine. 2025;55:127032.
   PubMed     Abstract available
   
   
   April 2025
5. PARVEEN S, Rath PP, Tabrez S, Khan S, et al
   Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.
   Vaccine. 2025;54:126993.
   PubMed     Abstract available
   
   
   
6. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
   Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
   Vaccine. 2025;53:127076.
   PubMed     Abstract available
   
   
   
7. DESHMUKH B, Khatri D, Kochar SK, Athale C, et al
   In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum.
   Vaccine. 2025;53:126952.
   PubMed     Abstract available
   
   
   
8. MO AX, McGugan G, Pesce JT
   Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
   Vaccine. 2025;54:127009.
   PubMed     Abstract available
   
   
   February 2025
9. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
   Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
   Vaccine. 2025;50:126783.
   PubMed     Abstract available
   
   
   January 2025
10. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    PubMed     Abstract available
    
    
    October 2024
11. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    PubMed     Abstract available
    
    
    July 2024
12. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    PubMed     Abstract available
    
    
    
13. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    May 2024
14. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
15. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    April 2024
16. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    March 2024
17. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    February 2024
18. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
19. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    November 2023
20. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    
21. HAYASHI CTH, Cao Y, Zavala F, Simonyan H, et al
    Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences.
    Vaccine. 2023;41:6824-6833.
    PubMed     Abstract available
    
    
    August 2023
22. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    May 2023
23. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    PubMed     Abstract available
    
    
    April 2023
24. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malaria is free of charge.